Tucatinib (Tucatinib) Detailed Medication Instructions for Patients in Chinese

Ⅰ. Indications

Tucatinib is indicated for the treatment of patients with HER2-positive breast cancer, especially those whose disease has progressed despite multiple anti-HER2 therapies, such as trastuzumab, pertuzumab, and T-DM1. Tucatinib (Tucatinib) Usually used in combination with trastuzumab and capecitabine, and is particularly effective in patients with brain metastases.

Ⅱ. Mechanism of action

Tucatinib is an oral, small-molecule tyrosine kinase inhibitor that specifically targets the HER2 receptor. By highly selectively inhibiting the tyrosine kinase activity of HER2, tucatinib blocks the activation of the HER2 signaling pathway, thereby inhibiting the growth and spread of cancer cells.

Ⅲ. Pharmacology

Tucatinib reduces cancer cell proliferation and survival by blocking the HER2 signaling pathway. It can penetrate the blood-brain barrier and effectively act on HER2 positive cancer cells in the brain. Tucatinib has high bioavailability and is rapidly absorbed after oral administration. The peak concentration is reached within 1-2 hours.

Ⅳ. Dosage and Usage

The recommended dose is 300mg twice daily, taken continuously. Tucatinib (Tucatinib) should be taken with food to improve drug absorption. Patients should take medicine on time as directed by their doctor and should not adjust the dosage without authorization.

Ⅴ. Side Effects

Common side effects include:

1.Diarrhea: Patients may have varying degrees of diarrhea, and if severe, seek medical attention promptly.

2.Hand-foot syndrome: manifests as redness, swelling, pain, and peeling of the skin on the palms and soles of the feet.

3.Nausea and vomiting: Some patients may experience mild to moderate nausea and vomiting.

4. Abnormal liver function: may lead to elevated levels of transaminases (ALT and AST).

5.Fatigue: Patients may feel extremely tired and weak.

6.Skin rash: Some patients will develop a mild rash.

Ⅵ. Warnings and Precautions

1.Diarrhea management: Patients should pay attention to replenishing water and use anti-diarrheal drugs if necessary.

2.Liver function monitoring: Liver function tests should be performed regularly during treatment to detect abnormalities in time.

3.Hand-foot syndrome care: Use moisturizer to avoid prolonged friction and pressure.

4.Drug Interactions: Avoid concurrent use with strongCYP3A4inhibitors or inducers.

Ⅶ. Contraindications

Contraindicated in patients allergic to tucatinib and its components.

Ⅷ. Drug interactions

Tucatinib is mainly metabolized byCYP3A4. Concomitant use with strong CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) may alter the plasma concentration of tucatinib (tucatinib), affecting its efficacy and safety.

Ⅸ. Drug use for special groups

1.Pregnant and breastfeeding women:Tucatinib (Tucatinib) may be harmful to the fetus or infant and should be avoided by pregnant and breastfeeding women.

2.Children: There is currently no data on the safety and effectiveness of tucatinib (tucatinib) in children, and its use in children is not recommended.

3.Elderly patients: Elderly patients should adjust the dose appropriately according to their individual conditions and closely monitor side effects.

Tucatinib is a highly selective oral small molecule tyrosine kinase inhibitor for HER2-positive breast cancer. It effectively prevents the growth and spread of cancer cells by inhibiting the HER2 signaling pathway. Patients should strictly follow the doctor's instructions when using tucatinib (tucatinib), pay attention to monitoring side effects, and conduct regular health examinations. For special groups of people, special attention should be paid to the safety and applicability of drugs.